Isovue-m

Iopamidol is a non-ionic, water-soluble radiographic contrast agent used in X-ray and CT imaging to enhance the visibility of blood vessels, organs, and tissues.

The dosage of Iopamidol is highly individualized and is determined by the radiologist or attending physician based on the specific diagnostic procedure, the patient's body weight, and the vascular area being imaged.

• Cerebral Angiography: For visualizing the blood vessels in the brain, the typical dose ranges from 8 to 12 mL of a 300 mgI/mL solution per injection. Multiple injections may be required, but the total dose usually does not exceed 90 mL.
• Peripheral Arteriography: For imaging the legs or arms, doses typically range from 10 to 50 mL, depending on the specific artery being studied.
• Contrast-Enhanced CT (Body Imaging): For a standard CT scan of the chest, abdomen, or pelvis, the usual dose is 100 to 150 mL of a 300 mgI/mL solution, often administered via an automated power injector.
• Excretory Urography: To evaluate the kidneys, a dose of 25 to 50 mL of a 370 mgI/mL solution is common.

Iopamidol is approved for use in pediatric patients, including infants. Dosing in children is strictly based on body weight to ensure safety.

• General Pediatric Dosing: The typical dose for many procedures is 1.0 mL to 3.0 mL per kilogram (kg) of body weight.
• Maximum Limits: The total dose in children should generally not exceed 3.0 mL/kg or a total of 100 mL, whichever is lower, unless specifically directed by a pediatric radiologist.
• Neonates: In newborns, healthcare providers exercise extreme caution due to the immature state of the infant's kidneys and the potential for shifts in fluid balance.

Renal Impairment

Patients with pre-existing kidney disease are at a higher risk for Contrast-Induced Nephropathy (CIN), a sudden decline in kidney function following contrast administration. For these patients, healthcare providers may use the lowest effective dose of Iopamidol and ensure the patient is aggressively hydrated with intravenous fluids before and after the procedure. In cases of severe renal failure, the procedure may be postponed or an alternative imaging method (like ultrasound or non-contrast MRI) may be chosen.

Hepatic Impairment

Since Iopamidol is excreted almost exclusively by the kidneys, dosage adjustments are generally not required for patients with liver disease. However, the patient's overall clinical status must be considered.

Elderly Patients

Older adults are more likely to have reduced renal function and underlying cardiovascular disease. Healthcare providers typically assess creatinine clearance (a measure of kidney health) in elderly patients before administering Iopamidol. Dosing is often conservative, starting at the lower end of the range.

Iopamidol is not a medication you take yourself at home. It is administered exclusively by trained medical professionals in a hospital or imaging center setting.

• Preparation: You may be asked to fast (not eat) for several hours before the procedure to reduce the risk of nausea or complications if an allergic reaction occurs.
• Hydration: It is vital to drink plenty of water before and after the procedure (unless instructed otherwise for medical reasons) to help your kidneys flush the contrast agent out of your system.
• Administration: The agent is usually injected through an intravenous (IV) line. You may feel a brief sensation of warmth or a metallic taste in your mouth during the injection; this is normal.
• Storage: In the clinical setting, Iopamidol is stored at room temperature (20°C to 25°C) and protected from light. It should not be used if the solution is discolored or contains particulate matter.

Because Iopamidol is administered as a single dose for a specific diagnostic event, there is no "missed dose" in the traditional sense. If a scheduled imaging procedure is missed, it must be rescheduled with the imaging facility.

An overdose of Iopamidol is rare because it is administered by professionals using controlled volumes. However, if an excessive amount is given, it can lead to severe strain on the kidneys and cardiovascular system. Symptoms of overdose may include difficulty breathing, extreme fatigue, or signs of kidney failure (reduced urination). In the event of a significant overdose, especially in patients with poor kidney function, hemodialysis (blood filtering) may be used to rapidly remove the contrast agent from the body.

> Important: Follow your healthcare provider's dosing instructions and pre-procedure guidelines exactly. Do not adjust your fluid intake or fast without medical guidance.

Most patients tolerate Iopamidol well, but because it is a foreign substance injected into the vascular system, some physiological responses are common. These usually occur during or immediately after the injection and are typically short-lived:

• Sensation of Warmth or Flushing: Many patients report a "hot flash" feeling that travels through the body. This is caused by the contrast agent temporarily dilating blood vessels.
• Metallic Taste: A brief, strange taste in the mouth is frequently reported.
• Nausea: A mild feeling of stomach upset may occur, which is why fasting is often recommended before the scan.
• Injection Site Reactions: Mild pain, coldness, or bruising at the site where the IV was inserted.

Iopamidol is a diagnostic tool that must be used with caution, particularly in patients with a history of allergies or certain chronic health conditions. Before receiving Iopamidol, it is essential to disclose your full medical history to your radiologist. The most significant risks involve allergic-type reactions and potential damage to the kidneys. Patients who have had a previous reaction to any iodinated contrast media are at a five-fold increased risk of having another reaction.

As of 2024, there are no FDA black box warnings for Iopamidol. It is considered one of the safer non-ionic contrast agents available. However, the absence of a black box warning does not mean the drug is without risk; severe and fatal reactions have occurred, necessitating administration only in settings equipped for emergency resuscitation.

• Allergic Reactions / Anaphylaxis Risk: Severe, life-threatening allergic reactions (anaphylactoid reactions) can occur even in patients with no prior exposure to Iopamidol. These reactions are unpredictable. Patients with asthma, hay fever, or food allergies (especially shellfish, though the "shellfish-iodine" link is a common myth) may be at a slightly higher risk.

While there are no drugs that are strictly "contraindicated" in a way that prevents the use of Iopamidol in an emergency, certain combinations are avoided in elective settings:

• Metformin: While not a direct interaction, if Iopamidol causes sudden kidney failure, Metformin can accumulate in the body and cause a life-threatening condition called lactic acidosis. Most guidelines recommend stopping Metformin at the time of the procedure and withholding it for 48 hours afterward, resuming only after kidney function is confirmed to be normal.

• Nephrotoxic Drugs: Medications that can damage the kidneys should be avoided or used with extreme caution near the time of Iopamidol administration. This includes:
• NSAIDs (e.g., Ibuprofen, Naproxen)

There are very few absolute contraindications for Iopamidol, as it is often used in life-saving diagnostic situations. However, it should NEVER be used in the following case:

• Known Hypersensitivity to Iopamidol: If a patient has had a documented, severe anaphylactic reaction specifically to Iopamidol in the past, its use is absolutely contraindicated unless the diagnostic need outweighs the risk of death and the patient is pre-medicated in an intensive care setting.
• Intrathecal Administration of Specific Concentrations: High concentrations of Iopamidol (like 370 mgI/mL) are absolutely contraindicated for injection into the spinal fluid (myelography) as they are neurotoxic at that level.

These are conditions where the risk of using Iopamidol is higher, requiring a careful risk-benefit analysis by the physician:

Iopamidol is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Risk-Benefit: Iopamidol should be used during pregnancy only if clearly needed. While the drug itself does not appear to be a major teratogen (cause of birth defects), the radiation from the X-ray or CT scan itself poses a risk to the developing fetus.
• Thyroid Monitoring: If a pregnant woman receives Iopamidol, the newborn's thyroid function should be monitored after birth, as the iodine can cross the placenta and affect the fetal thyroid gland.

Iopamidol is excreted into human breast milk in very small amounts (less than 0.01% of the dose). Studies have shown that the amount of iodine an infant would receive through breast milk is negligible.

Iopamidol is a non-ionic, tri-iodinated, water-soluble, low-osmolar radiographic contrast medium. Its diagnostic efficacy is derived from the three iodine atoms attached to a benzene ring (the 5-acetamido-N,N'-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodoisophthalamide structure). These iodine atoms absorb X-ray photons via the photoelectric effect. Because the iodine concentration in the blood or organ becomes much higher than in the surrounding tissue, the X-ray beam is attenuated (blocked), creating a high-contrast image on the detector. As a non-ionic agent, Iopamidol does not dissociate in solution, which results in lower osmolality than older agents, significantly reducing the risk of osmotic-related side effects like pain or fluid shifts.

Iopamidol has no known therapeutic pharmacological effects. It does not bind to receptors or alter cellular function in its intended use. The "effect" is purely physical and immediate upon injection. The duration of the effect depends on the blood flow to the area (for angiography) or the rate of renal filtration (for urography). In a CT scan, the peak enhancement of organs like the liver occurs approximately 60-90 seconds after injection.